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Abstract
This study was aimed at tracing the molecular characteristics of carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates in
Italy with both pulsed-ﬁeld gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Two hundred and two CRAB isolates
were collected during 2004–2009, in two different surveillance periods, from 22 Italian hospitals that were representative for both dis-
tribution and infection. PFGE was performed, and the MLST scheme used was based on the gene sequence as published on the MLST
Pasteur website http://www.pasteur.fr/mlst. Representatives of the major European clones I (RUH 875) and II (RUH 134) were used as
controls. The two groups of isolates were characterized for their carbapenem resistance genes: 154 of 202 carried blaOXA-58 alone, 21
of 202 also carried blaOXA-23, and 27 of 202 carried blaOXA-23 alone. No isolates were positive for blaOXA-24. Genotype analysis of all
isolates identiﬁed four distinct patterns by PFGE, which correlated with four distinct sequence types (STs) by MLST. The distribution of
these four clusters in Italy conﬁrmed the propensity of A. baumannii for nosocomial cross-transmission in a vast geographical area. We
observed that clones A and B had similarities with European clone II and I respectively. By MLST, clone A was ST2, like European clo-
ne II, and clone B was ST1, like European clone I. PFGE and MLST showed the same discriminatory power and reproducibility. In addi-
tion, the two methods were concordant in deﬁning CRAB Italian clones and in correlating them with the two pan-European clones.
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Introduction
Acinetobacter baumannii is an important opportunistic patho-
gen that is rapidly evolving towards multidrug resistance
(MDR) and is involved in various nosocomial infections,
especially in intensive-care units (ICUs), with increasing fre-
quency [1–3]. This microorganism is usually associated
with severe hospital infections [4], which often need the
use of carbapenems as a last-resort treatment. However,
reduced susceptibility or resistance to carbapenems is
increasingly being observed among A. baumannii clinical iso-
lates [5–9].
Numerous nosocomial outbreaks have already been
reported in Italy, with many reports emphasizing the associa-
tion of antibiotic resistance and outbreak strains [10,11].
Extensive genotypic characterization has shown that clusters
of highly similar A. baumannii strains occur, representative of
distinct clonal lineages. Of these, the so-called European clo-
nes I, II and III are widely spread across Europe, and include
strains that are usually multidrug resistant and associated with
outbreaks of hospital infections [12–14]. Changes in the preva-
lence of carbapenem resistance genes of the OXA type in
A. baumannii circulating among the urban area of Rome have
recently been documented, with blaOXA-23 gradually replacing
blaOXA-58 [15]. It has been suggested that this phenomenon
could be related, at least in part, to the higher carbapenemase
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activity of blaOXA-23 than of blaOXA-58, which results in a higher
imipenem MIC and in a clear resistance phenotype for stains
carrying this determinant. However, extensive data on the
prevalence of these genes throughout Italy are still lacking.
To investigate the molecular epidemiology of A. baumannii,
a variety of typing systems have been developed, including
ribotyping, genome analysis with selective ampliﬁed fragment
length polymorphisms, randomly ampliﬁed polymorphic DNA
analysis, infrequent-restriction-site PCR, and pulsed-ﬁeld gel
electrophoresis (PFGE) [16,17]. PFGE restriction analysis of
chromosomal bacterial DNA has been used with excellent
results in epidemiological studies of numerous A. baumannii
outbreaks, and is currently regarded as the reference stan-
dard for epidemiological typing [18]. Another possible
approach involves the use of multilocus sequence typing
(MLST), a highly discriminative method based on the
sequence comparison of internal fragments of housekeeping
genes, which has been applied to a variety of bacterial patho-
gens, and, most recently, also to A. baumannii [19,20].
This national study was carried out with the aim of: (i)
obtaining epidemiological typing data for Italian carbapenem-
resistant Acinetobacter baumannii (CRAB) clinical isolates col-
lected during two different periods, using both PFGE and
MLST; (ii) establishing clonal relationships with European
clones; and (iii) assessing the actual prevalence of carbape-
nem resistance genes in the investigated isolates.
Materials and Methods
Bacterial strains
Two hundred and two CRAB non-replicate isolates, responsi-
ble for severe infections, were collected from 22 hospitals dis-
tributed in 14 towns in Italy during two different surveillance
periods (2004–2005 and 2008–2009). During the ﬁrst period,
120 isolates were obtained from 120 patients, and in the sec-
ond period, 190 isolates were obtained from 136 patients;
however, after elimination of duplicate strains, the total was
82. Clinical data collected included age, sex, number of days in
hospital prior to isolation, specimen types, wards, and type of
infection. Isolates were mainly obtained from lower respira-
tory tract infections and documented bloodstream infections;
only a limited number of isolates came from complicated skin
and skin structure infections, skin and skin structure infections,
intra-abdominal infections, and urinary tract infections. Isolates
were collected by standard methods, isolated in pure culture
on MacConkey agar plates, and identiﬁed with the Vitek 2 sys-
tem (bioMerieux, Marcy l’Etoile, France). Identiﬁcation at the
species level was centrally reconﬁrmed with the API 20NE sys-
tem (bioMerieux).
Molecular typing: PFGE and MLST
Genotyping of all organisms identiﬁed as being A. baumannii
was performed with ApaI digestion followed by PFGE, using a
method described previously [21]. Genomic DNA was pre-
pared in agarose plugs, and DNA restriction was carried out at
30C for 16 h. PFGE was performed in a CHEF DRII system
(Bio-Rad, Hercules, CA, USA), with pulses ranging from 0.5 to
15 s at a voltage of 6 V/cm at 14C for 20 h. Lambda 48.5-kb
concatamers (New England BioLabs, Beverly, MA, USA) were
used as molecular size markers. Isolates showing three or
fewer band differences were regarded as a single PFGE type,
according to the criteria described previously by Tenover et al.
[22]. MLST was performed on 21 isolates, selected on the basis
of the different PFGE types and subtypes: in particular, ﬁve iso-
lates belonging to PFGE type A and two isolates belonging to
PFGE type B from both study periods, three type C isolates,
and four type D isolates. Representatives of major European
clones I (RUH 875) and II (RUH 134) were used as controls.
Genotyping by MLST was performed with primers and
conditions described on the Pasteur website http://www.pas-
teur.fr/mlst, with the exception of rpoB ampliﬁcation, which
was performed with primers rpoB-f (5¢-GGCGAAATAGTAG
AACCAC-3¢) and rpoB-r (5¢-AGCTTCGAAGTTGTAACC-
3¢), designed on the basis of a published sequence
(CU459141). All PCR ampliﬁcations were carried out under
the following conditions: 30 cycles of denaturation at 94C
for 1 min, annealing at 53C for 1 min, and extension at
72C for 2 min, preceded by a 5-min denaturation at 94C
and followed by a 10-min extension at 72C. PCR products
were directly puriﬁed from the reaction mixture with the
QIAquick PCR puriﬁcation kit (Qiagen, Hilden, Germany),
according to the manufacturer’s recommendations. Puriﬁed
products were sequenced by an external facility (BioMolecu-
lar Research), and results were analysed with the VectorNTI
software package and compared with the A. baumannii data-
base on the MLST website http://www.pasteur.fr/mlst.
PCR of carbapenem resistance genes
PCR assays were carried out by using previously published
primers for ampliﬁcation of genes encoding carbapenemases
(blaIMP, blaVIM, blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, and
blaOXA-58) [23,24]. The blaOXA51-like gene was also evaluated
as an identiﬁcation marker [25].
The PCR assays were performed directly on colonies, and
the obtained products were puriﬁed and sequenced (BioMo-
lecular Research).
Antimicrobial agents and MIC determination
MIC determinations were performed by microdilution in
cation-adjusted Mueller–Hinton broth, in accordance with
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the 2010 CLSI guidelines [26]. The following antibiotics were
tested: meropenem, imipenem, piperacillin, piperacillin–
tazobactam, aztreonam, ceftazidime, cefepime, ciproﬂoxacin,
amikacin, gentamicin, colistin, and tigecycline. MIC values
were interpreted with category designations according to
CLSI criteria. No interpretive criteria have been approved
for tigecycline when testing Acinetobacter spp. [27]. Escherichia
coli ATCC 25922 was used as control.
Results
Isolates, wards, and clinical specimens
Table 1 shows the characteristics of CRAB isolates collected
during the two study periods. In 2004–2005, 120 isolates
(51% from males and 49% from females) were included, with
patient ages ranging from 1 to 94 years (mean age, 68 years).
During 2008–2009, a further 82 isolates were collected (70%
from males and 30% from females), with patient ages ranging
from 7 to 90 years (mean age, 62 years). Signiﬁcant changes
in the presence of CRAB isolates were observed in ICU
patients between the two periods, with an incidence of 74%
in the ﬁrst period, and a reduction to 40% in the second
period. In contrast, in medicine and pneumology wards,
increases of 25% and 7%, respectively, were observed. This
discrepancy is attributable to the duplicates being eliminated
from the second period.
In both periods, approximately 5% and 6% of the isolates
came from surgery units and from transplantation units,
respectively. All isolates were collected from various types
of nosocomial infection, such as respiratory tract infections
(32% in 2004 and 35% in 2008), bloodstream infections, and,
less frequently, urinary tract infections.
Respiratory secretions, urine and blood were the most
common clinical specimens collected, without signiﬁcant dif-
ferences between the two periods.
Molecular typing: PFGE and MLST
To trace the molecular characteristics of the CRAB isolates,
they were all genotyped by PFGE and MLST. PFGE analysis
was able to classify the 120 isolates of 2004–2005 into three
PFGE clones, named A, B, and C, three main clone A sub-
types, A1, A2, and A3, and two main clone C subtypes, C1
and C2. The three PFGE clones coincided with sequence
types (STs) found by MLST. In fact, the three PFGE clones
belonged to three different STs (clone A was ST2, clone B
was ST1, and clone C was ST20). Ninety-two per cent of
isolates belonged to clone A (ST2), as shown in Table 2a.
PFGE clone B (ST1) and clone C (ST20) were found in
two hospitals of southern Italy, Bari and Palermo, respec-
tively. Six strains belonging to clone C were distributed in
two wards of a hospital and, in particular, one of these (C1)
was isolated in a medical unit and ﬁve (C1 and C2) in an
ICU.
As regards the strains collected in 2008–2009, clone A
(ST2) represented 81% of CRAB isolates, and clone B (ST1),
previously isolated only in Bari, persisted in this area and
was also found in two hospitals in central (Rome S. Pertini)
and northern (Novara) Italy (Table 2b).
Interestingly, a new PFGE clone, named clone D and
belonging to ST78, was detected in two hospitals in southern
Italy (Catania Policlinico; Naples Federico II) and in a hospital
in northern Italy (Novara), and represented 13% of the iso-
lates. The comparison among Italian and European clones I
and II highlighted the fact that PFGE clone A (ST2) was
related to European clone II, and PFGE clone B (ST1) was
related to European clone I (Fig. 1).
Antimicrobial agents, MIC determinations, and carbapenem
resistance genes
The results of the in vitro susceptibility testing in the two
study periods, expressed as percentage of resistance, are pre-
sented in Table 3. All isolates were resistant to meropenem
in both periods, whereas the activity of imipenem showed
some differences: 90.8% in 2004–2005 and 100% in 2008–
2009. Most A. baumannii isolates were multidrug resistant,
showing resistance to: b-lactams (piperacillin, piperacillin–
tazobactam, aztreonam, and ceftazidime), ﬂuoroquinolones
(ciproﬂoxacin), and aminoglycosides (gentamicin).
TABLE 1. Clinical characteristics of patients (N = 202) with
carbapenem-resistant Acinetobacter baumannii infections
Patient
characteristics
No. (%) of
patients,
2004–2005
No. (%) of
patients,
2008–2009
Sex
Male 61 (51) 57 (70)
Female 59 (49) 25 (30)
Age (years), range (mean) 1–94 (68) 7–90 (62)
Admission: ICU 89 (74) 33 (40)
Non-ICU wards
Medicine 16 (14) 31 (39)
Surgery 8 (6) 4 (5)
Transplantation 6 (5) 7 (8)
Pneumology 1 (1) 7 (8)
No. of days in hospital prior
to isolation, range (mean)
3–60 (32) 5–57 (31)
Severe infections
Lower respiratory tract 39 (32) 29 (35)
Blood 25 (21) 14 (17)
Urinary tract 9 (7) 7 (8)
Other 47 (40) 32 (40)
Specimens
Lung 53 (44) 33 (41)
Blood culture 17 (14) 15 (18)
Urine 10 (9) 9 (16)
Other 40 (33) 25 (31)
Total 120 82
ICU, intensive-care unit.
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All of the 120 isolates obtained in the ﬁrst period were
resistant to piperacillin and ceftazidime, and 98% were resis-
tant to aztreonam and ciproﬂoxacin. Only one isolates was
resistant to colistin, and the results concerning the activity
of tigecycline showed moderate activity. Only eight of 120
multidrug-resistant isolates showed tigecycline MIC values
between 4 and 8 mg/L.
Increased levels of resistance to all antibiotics tested were
observed during the second period; 23 of 82 isolates had
MICs of 4 and 8 mg/L for tigecycline, and all isolates were
susceptible only to colistin.
All isolates were characterized for their carbapenamase
genes: they were all metallo-b-lactamase-negative, but positive
for carbapenem-hydrolysing class D b-lactamase genes. All of
the clones found in the ﬁrst period carried blaOXA-58, and only
one of them, clone C, carried both blaOXA-58 and blaOXA-23. In
the second period, blaOXA-58 was detected in 40 of 82 isolates
belonging to clones A, B, and D. Fifteen of 82 isolates belong-
ing to clone A and B carried both blaOXA-58 and blaOXA-23.
Finally, 27 of 82 isolates collected at S. Matteo hospital in Pavia
carried blaOXA-23, and all isolates belonged to clone A; there-
fore, this clone was responsible for an outbreak in this hospi-
tal. All isolates were positive for blaOXA-51, the carbapenemase
gene that is intrinsic to this species.
Discussion
A. baumannii is one of the most widespread microorganisms
responsible for global outbreaks, displaying ever increasing
rates of resistance [28]. There are reports of multidrug-
resistant A. baumannii strains from Europe and North Amer-
ica, Russia, Brazil, China, and Tahiti [29–33]. Multidrug-resis-
tant strains often spread, causing outbreaks throughout
entire cities, countries, and continents [34]. Furthermore,
the importation of multidrug-resistant strains from areas
with high rates of antimicrobial resistance to areas with his-
torically low rates, such as from Spain to Norway, has been
demonstrated. More recently, several cases of UK and US
TABLE 2. Genotypic and epidemiological analysis of strains isolated during: (a) 2004–2005; and (b) 2008–2009
No. of strains PFGE type PFGE subtype ST Hospitals
OXA content
58 58 + 23
(a)
110 A A1, A2, A3 2 Bari, Naples Federico II, Naples Cardarelli,
Naples Tufano, Rome S. Camillo, Avellino,
Pavia S. Matteo, Pavia Maugeri, Reggio
Calabria, Florence, Turin, Foggia and Varese
110 0
4 B 1 Bari 4 0
6 C C1, C2 20 Palermo 0 6
120 114 6
Clone II (RUH 134) A – 2
Clone I (RUH 875) B – 1
(b)
OXA content
58 58 + 23 23
66 A A1, A2, A3 2 Bari, Naples Federico II, Catania OVE, Rome
Gemelli, Rome Umberto I, Palermo
Chiarini, Milan and Pavia S. Matteo
27 12 27
5 B 1 Novara, Rome S. Pertini and Bari 2 3
11 D 78 Naples Federico II, Novara and Catania
Policlinico
11 0
82 40 15 27
PFGE, pulsed-ﬁeld gel electrophoresis; ST, sequence type.
R R
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FIG. 1. PEGE Apa I proﬁles of representative A. baumannii strains
including European clones I (RUH 875) and II (RUH 134). k: molecu-
lar size marker in kilobases. Lane 1 clone A2/ST 2, lane 2 clone
A3/ST2, Lanes 3–4-clone B/ST 1, lanes 5–6–7–8-clone A1, lane 9–10
clone C2/ST20, lanes 11–12 clone C1/ST 20 and lane 13–14 clone
D/ST 78.
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military and non-military personnel returning from opera-
tions in Iraq and Afghanistan, and harbouring infections
caused by CRAB, have been reported [35,36].
CRAB is now an issue in many European countries;
although information on the prevalence of carbapenem resis-
tance is difﬁcult to obtain, it appears from the outbreak liter-
ature that carbapenem resistance rates are higher in Turkey,
Greece, Italy, Spain, and England, and are still rather low in
Germany and in The Netherlands.
In Europe, outbreaks are especially attributable to three
A. baumannii clones (the so-called European clones I, II, and
III) [37]. Clone I was isolated in Spain, Poland, and the UK,
and clone II was isolated in Italy, Spain, Portugal, France,
Greece, the UK, and Turkey [10,38,39]. A third pan-Euro-
pean clone, clone III (LUH5875), which has probably per-
sisted in European hospitals since the 1990s, has recently
been described in France, The Netherlands, Italy, and Spain
[14].
Our study revealed the distribution of four distinct A. bau-
mannii epidemic clones isolated in the two periods 2004–
2005 and 2008–2009. The vast majority of all isolates in both
periods belonged to PFGE clone A (ST2), distributed
throughout Italy and related to the European clone II. In par-
ticular, clonal subtype A1 spread in the ICU wards of Bari
and Naples Federico II hospitals from 2004 to 2009. In both
periods, clonal subtype A2 was found in different wards (sur-
gery in 2004; medicine and transplant in 2008) at Gemelli
hospital in Rome, and clonal subtype A3 only in the medicine
ward at Bari hospital, with an increase in 2008 (nine iso-
lates). All isolates belonging to clone B (ST1) were obtained
in the hospital of Bari in both periods, whereas in Rome
S. Pertini and Novara hospitals, they were isolated only in
2008 (in the second period). Clone C (ST20) was found for
the ﬁrst time in Italy only in 2004, but belonged to the same
clonal complex (clonal complex 1) [40]. Eleven isolates of
clone D (ST78) were found in three hospitals, with poly-
clonal spread in the Novara hospital (clones D and B) and in
Naples Federico II (clones D and A). Interestingly, their
detection at Naples Federico II occurred during 2008, sug-
gesting the spread of a new A. baumannii epidemic clone in
the same ICU, owing to colonization of patients, as already
demonstrated in a previous study [41]. The polyclonal spread
occurred also in Rome, especially in the second period, as
clones A1, A2 and B were found in all of the Rome
hospitals.
All the above data show that most of these multidrug-
resistant epidemic strains were spread in the south of Italy.
In the present study, 68% of CRAB strains belonged to
European clone II, suggesting its potential to be particularly
successful in spreading all around Europe and Italy.
With regard to the mechanism of carbapenem resistance
in the Italian isolates, neither metallo-b-lactamase activity nor
the genes encoding these enzymes were detected in any of
the studied isolates. In contrast, the genes encoding carbape-
nem-hydrolysing class D b-lactamases were found in all iso-
lates, indicating that carbapenem resistance is caused by
acquired carbapenamases.
Since 1993, the year in which the ﬁrst acquired OXA
enzyme was found [42], the spread of this acquired mecha-
nism has been well documented [43], as has the role of clo-
nal spread of the major European lineages. Our results show
the presence of blaOXA-23 and blaOXA-58 alone and, in a few
TABLE 3. MIC distribution and antibiotic susceptibility of Acinetobacter baumannii (N = 202).
20082004MIC (mg/l)
Antibiotics 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 (%R) 
Imipenem               5 6 22*   42**
74 
          9
11 
     10
2 
         12 9 90,8 100 
Meropenem                   12         8
8 
          8
52 
      14
32 
      24
16 
      28 100 100 
Piperacillin 120 82 100 100 
Piperacillin/   
Tazobactam 3 3
48 2            
3            3
2           
65
68           
5 58. 3 85.4
Aztreonam 2 2 116      12           51 19 98. 3 100.0 
Ceftazidime 3 3               2             38
120         
3         22 11 100.0 90.2 
Cefepime 3
4  
         3    
30 2            
 5
72 
       32
12          
3           33 3 70.0 86.6 
Ciprofloxacin 
2 2           
47
116       
35 98. 3 100.0 
Amikacin 2 8
34 
    10
2 19 
         8
65         
16         34 4 54.2 75.6 
Gentamicin 2 3
25 1 69         
40
25         
27            10 78. 3 93.9 
Colistin 15 19       60
19 34
      22
32 1 0.8 0 
Tigecycline 10
2
           5
6 27
      10
77
     34
6  
        22
2            
1 -   -   
*2004–2005, **2008–2009.
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isolates, together. The recent observation of an increase in
meropenem MICs resulting from the presence of OXA-23
strains [15] was not conﬁrmed in our isolates. The high level
of carbapenem resistance in our isolates does not correlate
with the presence of blaOXA-58, blaOXA-23, or both together:
the different expression of intrinsic chromosomal blaOXA-51-
like genes could affect the MIC values obtained (L. Pagani,
personal observation).
Furthermore, the coexistence of blaOXA-58 and blaOXA-23
found in our isolates, recently reported by Higgins et al. [44]
in a molecular epidemiology study focused on the distribu-
tion of carbapenemase genes in A. baumannii worldwide, has
not been described in Italy before. The increased frequency
of blaOXA-23 was attributable to the spread of this successful
PFGE type A.
All CRAB isolates described in the present study showed a
similar anti-biotype pattern, characterized by resistance to all
of the antibiotics tested except tigecycline and colistin, which
remain the drugs of choice for the treatment of infections
caused by Gram-negative multidrug-resistant isolates [27,45].
In conclusion, Italian CRAB diffusion is attributable to the
spread of European clone II, which has acquired OXA-23
alone or in association with OXA-58 or OXA-51. New STs
have emerged in Italy, and, in our experience, PFGE and
MLST, chosen for epidemiological investigation, were equally
suitable: PFGE was more useful for local outbreak investiga-
tions, and MLST was convenient for establishing relatedness
with clones that have spread globally [46]. Further studies to
monitor resistant gene content and expression are needed.
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